AstraZeneca chief quits CSL board over $50 billion acquisition

AstraZeneca chief executive Pascal Soriot will leave CSL’s board just months after being appointed over fears of a potential future conflict of interest between the two biotechnology giants.

Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player. Mr Soriot was not set to be directly involved in discussions about the AstraZeneca vaccine production and it was planned he would abstain from board issues where there was a potential conflict of interest.

MsEmmaK I cant understand why no one is providing information on the CSL: manufacturing of AZ vaccine in Melbourne

MsEmmaK Are any Liberal involved in insider trading in this company ?

Portugal Últimas Notícias, Portugal Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

AstraZeneca chief quits CSL board over $50 billion acquisitionAstraZenaca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup. Too late insider trading information already used
Fonte: theage - 🏆 8. / 77 Consulte Mais informação »